Tandem Diabetes Care (Nasdaq:TNDM) today announced a new insulin pump integration with Abbott (NYSE: ABT) CGM.
Our sister site, Drug Delivery Business News, reports today that the companies agreed to pair the t:slim X2 automated insulin delivery (AID) system with the FreeStyle Libre 3 Plus continuous glucose monitor (CGM).
This marks the latest pairing of automated insulin delivery (AID) and continuous glucose monitor (CGM) technologies between the companies. They announced the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump in January 2024. Just last week, the companies announced the future pairing of Tandem systems with Abbott’s under-development dual glucose-ketone sensor.
Abbott’s FreeStyle Libre 3 Plus is the company’s latest-generation CGM designed for insulin pump integration. Its readings every minute can help insulin pumps adjust to users’ needs. Tandem designed its advanced hybrid closed-loop automated insulin delivery system to predict and help prevent high and low blood sugar.
Get the full story at our sister site, Drug Delivery Business News.
